Back to news

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Globe Newswire•16/11/2026•07:15 ET
0

Key Highlights

  • ➤Cash, equivalents and investments totaled $463.4 million at September 30, 2026
  • ➤ZEPHYR-2 Phase 3 schizophrenia trial start-up activities initiated; topline results expected in 2028
  • ➤VISTA Phase 2 Alzheimer’s disease psychosis trial enrollment continues; topline results expected second half of 2027
  • ➤Third-quarter net loss widened to $51.6 million from $29.4 million year over year
  • ➤R&D expenses rose to $44.2 million from $27.1 million year over year

Expert Statements

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics

“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market”

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics

“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics

“We also see a compelling opportunity for ML-007C-MA in Alzheimer’s disease psychosis, where its clinical profile offers the potential for meaningful differentiation.”

Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics

“With our cash position expected to fund operations through 2028, we are well-positioned to advance both programs while maintaining strategic and financial flexibility.”

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028

Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027; ML-007C-MA holds FDA Fast Track designation in ADP

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in